Combination Tests Could Distinguish Between Malignant Tumor Or Benign Cyst

The results of a study presented at the Society of Gynecologic Oncology’s 39th Annual Meeting on Women’s Cancer offer a promising development on the path toward better management of ovarian cancer. Researchers say testing women suspected of having ovarian cancer for a combination of proteins, or biomarkers in the blood called HE4 and CA 125, could be the key to predicting a woman’s risk for the disease dubbed the “silent killer.

More: continued here

Filed under: Women's Health / OBGYN on March 15th, 2008